Publication Name	World Journal of Gastroenterology
Manuscript ID	99692
Country	China

Received	2024-07-28 07:29
Peer-Review Started	2024-07-28 07:29
To Make the First Decision
Return for Revision	2024-09-07 17:21
Revised	2024-09-21 16:34
Second Decision	2024-09-26 02:36
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-09-26 06:19
Articles in Press	2024-09-26 06:19
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-09-29 00:11
Publish the Manuscript Online	2024-10-16 06:29

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Letter to the Editor
Article Title	Tofacitinib for ulcerative colitis: A promising treatment option
Manuscript Source	Unsolicited Manuscript
All Author List	Zong-Qiang Han and Li-Na Wen
ORCID	Author(s) ORCID Number Li-Na Wen http://orcid.org/0000-0001-6507-2978
Funding Agency and Grant Number	Funding Agency Grant Number The Scientific Research Cultivation Fund of Capital Medical University PYZ23175
Corresponding Author	Li-Na Wen, Doctor, Research Associate, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, No. 10 Tieyi Road, Yangfangdian Street, Haidian District, Beijing 100038, China. wenlina3074@bjsjth.cn
Key Words	Tofacitinib; Ulcerative colitis; Efficacy; Safety; Clinical trials
Core Tip	Tofacitinib can effectively alleviate ulcerative colitis (UC) without being affected by previous tumor necrosis factor antibody therapy. UC may recur after discontinuation of medication, but symptoms will be relieved after resuming tofacitinib administration. While demonstrating effectiveness, tofacitinib has adverse reactions such as herpes zoster and inflammatory reactions. These findings provide doctors with a reference for treating UC in clinical practice. However, more prospective cohort study data are still needed to provide more accurate evidence for the clinical application and safety of tofacitinib.
Publish Date	2024-10-16 06:29
Citation	<p>Han ZQ, Wen LN. Tofacitinib for ulcerative colitis: A promising treatment option. <i>World J Gastroenterol</i> 2024; 39(40): 4386-4392</p>
URL	https://www.wjgnet.com/1007-9327/full/v30/i40/4386.htm
DOI	https://dx.doi.org/10.3748/wjg.v30.i40.4386

Full Article (PDF)	WJG-30-4386-with-cover.pdf
Manuscript File	99692_Auto_Edited_081041.docx
Answering Reviewers	99692-answering-reviewers.pdf
Audio Core Tip	99692-audio.mp3
Conflict-of-Interest Disclosure Form	99692-conflict-of-interest-statement.pdf
Copyright License Agreement	99692-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	99692-foundation-statement.pdf
Non-Native Speakers of English Editing Certificate	99692-non-native-speakers.pdf
Peer-review Report	99692-peer-reviews.pdf
Scientific Misconduct Check	99692-scientific-misconduct-check.png
Scientific Editor Work List	99692-scientific-editor-work-list.pdf
CrossCheck Report	99692-crosscheck-report.pdf